FTC Calls Foul on CBD and Cannabis Marketing Claims During COVID-19 Pandemic

In this article published in the New Jersey Law Journal, Wilentz attorneys Michael F. Schaff and Lisa Gora discuss the Federal Trade Commission enforcement actions against cannabis companies that advertise CBD products as effective in preventing or treating COVID-19 without obtaining approval from the United States Food and Drug Administration.

This article is reprinted here with permission from the June 8 issue of the New Jersey Law Journal. © 2020 ALM Media Properties, LLC. Further duplication without permission is prohibited. All rights reserved.

Attachment: FTC Calls Foul on CBD and Cannabis Marketing Claims During COVID-19 Pandemic